Reacción a "Drug identified as “near-universal” treatment for rare disease"

In my opinion, the title of the press release does not reflect what is shown in the article. I think the idea has been overgeneralised, as the article clearly states that a pharmacological chaperone (Tolvaptan) [molecules capable of binding to proteins] is effective against mutations in the vasopressin V2R receptor. However, there is a world of difference between this and generalising that the same chaperone is functional at an almost universal level for rare diseases, as indicated by the title of the press release. In my opinion, the press release should indicate the specific relationship between the chaperone and the receptor, without generalising its use for other rare diseases.